Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) SEC filings page on Stock Titan provides structured access to the company’s U.S. regulatory disclosures. As a British Columbia–incorporated, globally active pharmaceutical issuer with common shares listed on the New York Stock Exchange and Toronto Stock Exchange, Bausch Health files a variety of documents with the U.S. Securities and Exchange Commission under Commission File Number 001-14956.
Investors can review current reports on Form 8-K that describe material events such as exchange offers for senior secured notes, amendments to credit agreements at Bausch Health and Bausch + Lomb, completion of acquisitions like DURECT Corporation, quarterly financial results, shareholder meeting outcomes and other significant corporate actions. These filings also summarize key terms of new 10.00% Senior Secured Notes due 2032, related indentures and collateral arrangements, including pledges of Bausch + Lomb shares.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide more comprehensive detail on Bausch Health’s segments—Salix, International, Solta Medical, Diversified Products and Bausch + Lomb—along with risk factors, management’s discussion and analysis and notes on non-GAAP metrics the company uses, such as organic revenue growth and adjusted EBITDA. Proxy materials and governance-related filings give additional insight into matters like the Amended and Restated Shareholder Rights Plan Agreement and shareholder voting results.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users understand changes in debt structure, covenant terms, segment performance and strategic transactions without reading every page. Real-time updates from EDGAR, along with visibility into items such as potential insider transaction reports on Form 4, allow users to monitor how Bausch Health reports its financial condition, capital structure decisions and corporate governance developments over time.
John Paulson, through managed funds, acquired 34,721,118 shares of Bausch Health Companies Inc. at $9 per share on 08/14/2025, increasing the funds' reported beneficial ownership to 70,755,869 shares. The Form 4 shows the purchase was reported as an indirect holding by the Funds managed by Paulson, and the filing includes a standard disclaimer that Paulson disclaims beneficial ownership except for any pecuniary interest. The transaction reflects a sizable increase in reported stake via managed accounts.
Paulson & Co. Inc. reported an initial Form 3 disclosing that certain funds it manages hold 70,755,869 shares of Bausch Health Companies Inc. (BHC). The filing, dated 08/14/2025, lists Paulson as the investment manager and notes John Paulson as the controlling person; the shares are indirectly owned by the Funds.
John Paulson, a director and the controlling person of Paulson Capital Inc., reported purchases of Bausch Health Companies common stock executed by funds he manages. The filings show three purchases: 2,000,000 shares at $6.35, 1,156,640 shares at $6.88, and 86,409 shares at $7.06, totaling 3,243,049 shares. After these transactions the reporting person’s indirect beneficial ownership is stated as 36,034,751 shares. The shares are held by managed funds and the report includes a disclaimer that the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. No derivative securities were reported on the form.
Bausch Health is asking shareholders to ratify a shareholder rights plan at a Special Meeting to be held via webcast on October 7, 2025 (record shareholders as of August 18, 2025 may vote). The Board adopted the Rights Plan on April 14, 2025 and issued one Right for each Voting Share outstanding at the Record Time. The Rights are intended to ensure all shareholders are treated equally in any unsolicited take-over bid and to discourage creeping acquisitions.
The Rights convert into purchase rights after a defined Separation Time if a person becomes an Acquiring Person (generally at a 20% Beneficial Ownership threshold). The Exercise Price is set at three times the 20-day average Market Price, and a Flip‑In Event can lead to significant dilution for an acquiror. The TSX has given conditional acceptance, and the Rights Plan requires reconfirmation by shareholders every third annual meeting to remain effective.